PHARMACY

Lilly Diabetes donates diabetes camp scholarships

BY Allison Cerra

INDIANAPOLIS and ALEXANDRIA, Va. — Through a collaboration with the American Diabetes Association, the diabetes division of drug maker Eli Lilly has committed to send 89 children to diabetes camp this summer.

Lilly Diabetes said it donated the camp scholarships — a fund totaling $89,000 — to the American Diabetes Association’s 2012 camp scholarship fund. More than 400 diabetes camping programs exist worldwide serving approximately 30,000 youth with diabetes and their families, Lilly Diabetes said.

"Diabetes camps provide education on diabetes management and personal development that often lead to newfound confidence for many campers. Campers who may not have taken charge of their care before, can begin to feel empowered and eager to learn more about their own health and well-being," Lilly Diabetes VP Steve Sugino said. "Invaluable experiences like these are just a few of the many reasons that Lilly Diabetes supports diabetes camps through our collaboration with the American Diabetes Association."


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA approves new indication for Novartis’ Gleevec

BY Alaric DeArment

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Novartis that is designed to prevent tumors in the gastrointestinal tract from recurring after surgical removal, the agency said.

The FDA approved Novartis’ Gleevec (imatinib) for adults who have had gastrointestinal stromal tumors, or GIST, removed. The drug was specifically approved for people whose tumors are known as CD117-positive, which includes 95% of all GIST tumors.

The drug was originally approved in 2001 for a type of leukemia.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Savient appoints interim CEO

BY Allison Cerra

EAST BRUNSWICK, N.J. — A former Johnson & Johnson executive has been appointed to serve as interim CEO for Savient Pharmaceuticals.

Savient’s board of directors appointed David Norton to serve as interim CEO, succeeding current CEO John Johnson, who is leaving the company to become president, CEO and chairman-elect of biotechnology company Denderon. Savient’s board said it will conduct a search process for a permanent CEO.

Norton, who is a member of Savient’s board, formerly served as J&J company group chairman of global pharmaceuticals.

In related news, Louis Ferrari, Savient’s SVP North America commercial operations, has been promoted to the position of EVP and president of North America commercial operations.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?